Advertisement
U.S. markets open in 4 hours 50 minutes
  • S&P Futures

    5,209.75
    -5.00 (-0.10%)
     
  • Dow Futures

    39,227.00
    +4.00 (+0.01%)
     
  • Nasdaq Futures

    18,192.75
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,047.60
    -2.20 (-0.11%)
     
  • Crude Oil

    82.57
    -0.15 (-0.18%)
     
  • Gold

    2,154.10
    -10.20 (-0.47%)
     
  • Silver

    25.07
    -0.19 (-0.77%)
     
  • EUR/USD

    1.0847
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.51
    +0.18 (+1.26%)
     
  • GBP/USD

    1.2688
    -0.0040 (-0.32%)
     
  • USD/JPY

    150.4190
    +1.3210 (+0.89%)
     
  • Bitcoin USD

    64,079.48
    -3,549.12 (-5.25%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,729.06
    +6.51 (+0.08%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Actavis completes acquisition of Warner Chilcott

Actavis completes $8.5 billion acquisition of Irish drugmaker Warner Chilcott

Generic drug maker Actavis plc said Tuesday that it has completed its $8.5 billion all-stock acquisition of branded drug maker Warner Chilcott plc, creating the third-largest specialty pharmaceutical company in the U.S.

The deal, first announced in May, expands Actavis' women's health and urology business and gives it a range of dermatology and gastroenterology products.

The combined company has been incorporated in Ireland under the name Actavis plc. Warner Chilcott was already based in Ireland and the incorporation there could reduce the combined company's tax liabilities.

Actavis expects the deal will increase its adjusted earnings per share by more than 30 percent in 2014. The company plans to discuss the details of the deal and combined forecasts for the company during its third-quarter earnings call on Oct. 29.

Shares of Actavis slipped 31 cents to $143.69 by midmorning. Its stock has jumped roughly 70 percent since this time last year, with a major spike in May.

Advertisement